New combo therapy shows promise for Hard-to-Treat colorectal cancer
NCT ID NCT03388190
First seen Feb 14, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study tested whether adding an immunotherapy drug (nivolumab) to standard chemotherapy could help control metastatic colorectal cancer that is not sensitive to immunotherapy alone. The trial involved 80 adults with advanced disease who had not received prior treatment. The main goal was to see if the combination slowed cancer growth better than chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Oslo, 1478, Norway
-
Haukeland University Hospital
Bergen, 5021, Norway
-
Hospital of Southern Norway, Department of Oncology
Kristiansand, 4604, Norway
-
Oslo University Hospital
Oslo, 0424, Norway
-
St Olav's Hospital - Trondheim University Hospital
Trondheim, 7006, Norway
Conditions
Explore the condition pages connected to this study.